Ballicules.com

Clobetasol

TEMOVATE

What it isSuperpotent topical glucocorticoid-receptor agonist; psoriasis, lichen planus, and severe eczema.

Why this oneIt is standard first-line treatment for vulvar lichen sclerosus, despite usual caution with superpotent steroids on thin skin.

What limits itSkin atrophy and striae follow overuse; large areas or occlusion can suppress the adrenal axis, so keep courses brief and localized.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Corticosteroid-responsive dermatosesAdultApply thin layer twice daily (BID)50 g/week; 2 consecutive weeks

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Teratogenic in animals when given subcutaneously (cleft palate, skeletal defects); use during pregnancy only if potential benefit justifies risk.

Lactation Undefined

NO BOXED WARNINGS

Principal riskSkin atrophy and striae; axis suppression over large areas

Cost, est. cash$10–$300/month

Generic entry1994

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger0 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryC

Defining liabilityLocal tissue effects and irritation; systemic corticosteroid toxicity is uncommon at usual exposure.

Mechanism of action: Clobetasol ballicule

Clobetasol ballicule: receptor binding, kinetics and half-life diagram

Open Clobetasol in the interactive console ↗

Memory aids: mascots and interaction avatars

Clobetasol TEMOVATE mascot mnemonic cartoon
“Clobber tassel To motivate”

Open Clobetasol in the interactive console ↗